Understanding how genetics affect inflammation and treatment in HIV patients
Host genetic predictors of plasma IL-1b levels and pharmacogenomics of in vivo IL-1b blockade during treated HIV disease
This study is looking at how your genes affect a substance called IL-1β in the blood and whether blocking it can help reduce inflammation and improve health for people living with HIV who are on treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10653157 on NIH RePORTER |
What this research studies
This research investigates the role of host genetics in influencing levels of interleukin-1 beta (IL-1β) in the blood of individuals living with HIV. It aims to explore how blocking IL-1β can reduce inflammation and improve health outcomes for HIV patients on antiretroviral therapy. The study will utilize advanced data analysis techniques to assess the impact of IL-1β blockade on inflammation and the HIV reservoir, which is the persistent virus that remains despite treatment. Participants will be monitored for changes in inflammatory markers and overall health.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV who are currently on antiretroviral therapy and experiencing persistent inflammation.
Not a fit: Patients who are not living with HIV or those who are not on antiretroviral therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies that reduce inflammation and associated health risks for HIV patients.
How similar studies have performed: Previous studies have shown that IL-1β blockade can significantly reduce cardiovascular events and cancer mortality in the general population, indicating potential for success in this specific HIV context.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Lee, Sulggi Angela — University of California, San Francisco
- Study coordinator: Lee, Sulggi Angela
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.